Can adding RNA sequencing to germline genetic testing improve accuracy and clinical sensitivity over time compared to DNA sequencing alone?

In a recent study published in the Journal of American Medical Association (JAMA) Oncology, researchers from California investigated the diagnostic outcomes of concurrent sequencing of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) to detect the predisposition to hereditary cancer in 43,524 individuals.

They found that adding RNA sequencing to germline genetic testing for cancer increased the positive yield and improved the detection of variants in the participants.

Study: Diagnostic Outcomes of Concurrent DNA and RNA Sequencing in Individuals Undergoing Hereditary Cancer Testing. Image Credit: Cryptographer/Shutterstock.comStudy: Diagnostic Outcomes of Concurrent DNA and RNA Sequencing in Individuals Undergoing Hereditary Cancer Testing. Image Credit: Cryptographer/Shutterstock.com

Background

The advent of precision medicine has revolutionized cancer management by predicting an individual’s predisposition to cancer via testing for tumor biomarkers and germline variants.

An increasing amount of evidence suggests that specific systemic therapy in individuals with germline pathogenic variants (PVs) may be effective in high-risk patients, including those with a familial history of cancer.

Early and accurate genetic testing in these patients could help improve prognosis using advanced technology, including next-generation sequencing and multigene panel testing. Although most precision medicine approaches are DNA-based, the more recent inclusion of RNA-based techniques has shown promise in identifying individuals with germline cancer susceptibility.

Therefore, researchers in the present study assessed the effectiveness of paired DNA and RNA testing in individuals undergoing hereditary cancer screening and measured the impact of the approach on the positive yield and rate of identifying variants of uncertain significance (VUS).

About the study

Clinical and molecular data were obtained from 43,524 individuals undergoing paired DNA and RNA testing at a testing laboratory between March 2019 and April 2020. The median age of the participants was 54 years, and 85.7% were female.

About 65.1% of these individuals had a history of cancer, with breast cancer being the most common type, followed by colorectal and ovarian cancer. The cohort included participants from the following races: Ashkenazi Jewish, Asian, Black, Hispanic, non-Hispanic White, and others.

Various genes (n=18) associated with breast, colorectal, ovarian, and pancreatic cancer were included in the study. DNA sequencing, RNA analysis, and deletion and duplication analysis were performed.

Sequence variations were classified as pathogenic (P), likely pathogenic (LP), VUS, benign (B), or likely benign (LB) based on guidelines from the American College of Medical Genetics and Genomics and the Association for Molecular Pathology (ACMG/AMP).

The approach was aligned with the ClinGen Sequence Variant Interpretation splicing subgroup to extract splicing-related evidence and standardize variant classification while interpreting RNA data.

The splicing impact of variants was predicted using in silico modeling via SpliceAI. The percent splicing index and number/type of splicing events were measured in patients compared to control data to identify abnormal transcripts.

The changes in variant classification were monitored over time. RNA-impacted variants were identified as those reclassified due to RNA evidence. The statistical analysis involved using the chi-square test and Fisher exact test.

Results and discussion

As per the study, while positive results were observed in 11.2% of participants, VUS was observed in 20.1%. RNA evidence impacted variant classification in 549 cases that underwent paired RNA-DNA testing.

This additional evidence improved the classification of LB and LP in 33.9% of cases, leading to reclassification to B or P. Furthermore, VUS was reclassified as LB or B in 45.5% of cases. Clinically significant reclassifications were made in 73.3% of cases.

RNA-impacted cases improved the positive rate and decreased the VUS rate. The relative increase in diagnostic yield was estimated to be 1.9%, suggesting that in the absence of RNA evidence, 1 in 54 patients with P/LP variants would have received incorrect or undetected results. The diagnostic yield was observed to vary across races.

Interestingly, about 75.7% of P/LP and 73.6% of B/LB RNA-impacted cases had recurrent variants observed in more than one individual. As per the results, PVs were common, emphasizing the need for RNA sequencing for improved accuracy.

Overall, RNA sequencing improved the sensitivity and accuracy of cancer detection in traditionally undetected cases and supported the previous clinically actionable classifications made with limited evidence.

Despite the improved detection rate and accuracy obtained via RNA sequencing tests, their widespread application is limited by their high cost to laboratories. The study findings call for further research and highlight the need for increased collaboration and data sharing among healthcare practitioners and researchers.

Conclusion

In conclusion, the present study provides evidence of the efficacy of RNA sequencing in improving the identification of high-risk individuals, especially missed by traditional DNA-based approaches.

In the future, studies including a greater number of cancer susceptibility genes could help improve our understanding of the effect of RNA splicing on cancer genetics, with the ultimate aim of improving patient outcomes via early detection.

Journal reference:
Dr. Sushama R. Chaphalkar

Written by

Dr. Sushama R. Chaphalkar

Dr. Sushama R. Chaphalkar is a senior researcher and academician based in Pune, India. She holds a PhD in Microbiology and comes with vast experience in research and education in Biotechnology. In her illustrious career spanning three decades and a half, she held prominent leadership positions in academia and industry. As the Founder-Director of a renowned Biotechnology institute, she worked extensively on high-end research projects of industrial significance, fostering a stronger bond between industry and academia.  

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Chaphalkar, Sushama R.. (2023, November 08). Can adding RNA sequencing to germline genetic testing improve accuracy and clinical sensitivity over time compared to DNA sequencing alone?. News-Medical. Retrieved on October 31, 2024 from https://www.news-medical.net/news/20231108/Can-adding-RNA-sequencing-to-germline-genetic-testing-improve-accuracy-and-clinical-sensitivity-over-time-compared-to-DNA-sequencing-alone.aspx.

  • MLA

    Chaphalkar, Sushama R.. "Can adding RNA sequencing to germline genetic testing improve accuracy and clinical sensitivity over time compared to DNA sequencing alone?". News-Medical. 31 October 2024. <https://www.news-medical.net/news/20231108/Can-adding-RNA-sequencing-to-germline-genetic-testing-improve-accuracy-and-clinical-sensitivity-over-time-compared-to-DNA-sequencing-alone.aspx>.

  • Chicago

    Chaphalkar, Sushama R.. "Can adding RNA sequencing to germline genetic testing improve accuracy and clinical sensitivity over time compared to DNA sequencing alone?". News-Medical. https://www.news-medical.net/news/20231108/Can-adding-RNA-sequencing-to-germline-genetic-testing-improve-accuracy-and-clinical-sensitivity-over-time-compared-to-DNA-sequencing-alone.aspx. (accessed October 31, 2024).

  • Harvard

    Chaphalkar, Sushama R.. 2023. Can adding RNA sequencing to germline genetic testing improve accuracy and clinical sensitivity over time compared to DNA sequencing alone?. News-Medical, viewed 31 October 2024, https://www.news-medical.net/news/20231108/Can-adding-RNA-sequencing-to-germline-genetic-testing-improve-accuracy-and-clinical-sensitivity-over-time-compared-to-DNA-sequencing-alone.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
UC San Diego receives $8 million grant to study the genetics of substance use disorder